DNAPRINT GENOMICS PRODUCTS

DNAPrint™ genomics, Inc. is a cutting edge company. We are concentrating our efforts in four distinct areas; Pharmacogenomics, Forensics, Genotyping, and Consumer Products. Our aim is to continue to research and develop novel products and services in each of these market areas and to be a leader in genomic-based technologies.

ANCESTRYbyDNA™ 2.5:
DNAPrint™'s genealogy product, ANCESTRYbyDNA™ 2.5, is a pan-chromosomal assay for genetic ancestry. The test surveys 176 Ancestry Informative Markers (AIMs) to provide an inference of genetic ancestry or heritage. The AIMs were carefully selected from large-scale screens of the human genome; and are characterized by sequences of DNA that are more prevalent in people from one continent than another. Using complex statistical algorithms, the test can determine with confidence to which of the major bio-geographical ancestry groups, Sub -Saharan African, European, East Asian or Native American, a person belongs, as well as the relative percentages in cases of admixed peoples. It’s a great tool for those individuals or groups interested in more deeply understanding their ancestry and lineage, or for certain people (i.e. some adoptee of mixed heritage) learning about their genetic ancestry.

FORENSICS:
We recently introduced DNAWitness™2.5 to the forensics market. Law enforcement officers use this testing service to determine genetic heritage from DNA samples obtained from crime scenes, narrowing the potential suspect pool to a more focused group of likely candidates. The test enables law enforcement agencies to reduce both the cost and time needed to apprehend suspects. Current forensic DNA products in the market act like a fingerprint and can only be used to match DNA specimens. DNAPrint™ is the first forensic product that provides predictive capability. DNAWitness™ will provide the percentage of genetic make up amongst the four possible groups of Sub-Saharan African, Native American, East Asian, and European. When appropriate, DNAWitness™ allows for a breakdown of the European ancestry into four components: Northwestern European, Southeastern European, Middle Eastern and South Asian. The names of the components/groups is meaningful but not exact, since they are cast in modern-day terminology but the assay is an anthropological one that reports affiliation with populations who share common ancestry extending back many thousands of years. The real value of the percentages reported are as population (rather than individual) bar-codes, which are very useful for inferring certain elements of physical appearance.

PHARMACEUTICALS:
Over the next 10 to 15 years, the worldwide pharmaceutical market is expected to grow from about $300+ billion (2003 data on world-wide pharmaceutical industry reports) to over a trillion dollars, driven primarily by the flood of new drug targets some of them having been identified through genomics and through the co-development of drugs and accompanying genomics response tests. The primary objective of DNAPrint™‘s near term research and development efforts in pharmacogenomics will be to expand our library of predictive drug response tests to include multiple therapeutic areas which include commonly used FDA approved drug therapies. Longer term, this work will provide us the expertise to apply pharmacogenomics methods to our own developing drug pipeline, to reduce the risk and expense of the clinical trial process. A primary purpose of Phase II is for the drug-developer to learn how to improve the drug’s response and better target the patient population for the pivotal Phase III; if the drug works better in a segment of the population then the company can design more effective Phase III clinical trials to focus on that specific group of patients thereby maximizing the efficacy and minimizing the side effects of the new medication. However, most pharmaceutical companies and Clinical Research Organizations (CRO’s) that run the trials; still do not employ powerful genome-based methods to characterize their patients during the trial process. We hope that by using our technology, we will be able to target our drugs to segments of the population that are genetically compatible and thereby enjoy a higher trial and post-market success rate. In many respects, we hope our medicines will be more compatible with our patients over a longer period of time.

PATERNITY:
DNAPrint™ genomics, Inc. provides an affordable, confidential and accurate screening test service for paternity. Our paternity test is processed on ABI 3700 and 3100 equipment, state of the art analyzers that measure the Short Tandem Repeat (STR) units. Though these markers carry little ancestry information, they have been standardized over the past decade to serve as “DNA bar-codes” for human identification and first generation relationships. The test measures 16 loci (markers) and the 10 to 15 alleles that are associated with each loci and the combination of these alleles are like a fingerprint in that they are unique to each individual